Skip to content
value.today

Auron Therapeutics, Inc.

Total raised
$81 M
3 rounds on record
Latest round
$27 M
Dec 2024
First round on record
Dec 2020
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Auron Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2024$27 MNo. 3$10 to $50 million

Auron Therapeutics, Inc.: Raise no. 3, Dec 2024

Investors in this round

16 investors had bought by the notice of Dec 23, 2025: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$27 M of $42 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Katharine Yen · Executive Officer, Director
  • Alexandra Cantley · Director
  • Anna Duncan French · Director
  • Briggs Duncan Morrison · Director
  • Pini Duncan Orbach · Director
  • Serge Duncan Messerlian · Director
  • Victoria Duncan Richon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Katharine Yen, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Dec 23, 2025. Read the notice at the SEC.

equitySEC
Jul 2022$38 MNo. 2$10 to $50 million

Auron Therapeutics, Inc.: Raise no. 2, Jul 2022

Investors in this round

10 investors had bought by the notice of Oct 20, 2023: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$38 M of $48 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher Duncan Guiffre · Executive Officer
  • Katharine Yen · Executive Officer, Director
  • Alexandra Cantley · Director
  • Alon Duncan Lazarus · Director
  • Anna Duncan French · Director
  • Briggs Duncan Morrison · Director
  • Eric Duncan Shiozaki · Director
  • Victoria Duncan Richon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Katharine Yen, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 20, 2023. Read the notice at the SEC.

equitySEC
Dec 2020$15 MNo. 1$10 to $50 million

Auron Therapeutics, Inc.: Raise no. 1, Dec 2020

Investors in this round

25 investors had bought by the notice of Dec 16, 2020: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Katharine Yen · Executive Officer, Director
  • Alon Duncan Lazarus · Director
  • Anna Duncan French · Director
  • Isaac Ciechanover · Director
  • John Duncan Higgons · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Katharine Yen, President. Source: SEC Form D, newest notice filed Dec 16, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Auron Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2025).

    SEC Form D · Dec 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2025

That is all the official record says: Auron Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Auron Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 25 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Auron Therapeutics, Inc.
NameRoleNamed in
Katharine YenExecutive officerDec 2025
Christopher Duncan GuiffreExecutive officerOct 2023
Alexandra CantleyDirectorDec 2025
Anna Duncan FrenchDirectorDec 2025
Briggs Duncan MorrisonDirectorDec 2025
Katharine YenDirectorDec 2025
Pini Duncan OrbachDirectorDec 2025
Serge Duncan MesserlianDirectorDec 2025
Victoria Duncan RichonDirectorDec 2025
Alon Duncan LazarusDirectorDec 2024
Eric Duncan ShiozakiDirectorOct 2023
Isaac CiechanoverDirectorDec 2020
John Duncan HiggonsDirectorDec 2020